Current drug targets
MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation.
Xiang Huang, Shimei Zhang, Linjuan Wang, Yue Qiu, Min Zhao, Qiufang Chen
Published: 202610.2174/0113894501409916251103161912
Abstract
INTRODUCTION: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and the MET exon 14 skipping mutation is a key oncogenic driver, which promotes tumor progression and provides a new direction for precision therapy. METHODS: A…
Preview only. Read the full abstract at the source